Related Experiment Video
Updated: Jul 7, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC
Elaine M Jennings1, D Ross Camidge2, Shirish Gadgeel3
1Eli Lilly and Company, Indianapolis, IN.
Abstract:
Central nervous system (CNS) metastases are frequently diagnosed in patients with non-small cell lung cancer (NSCLC). Only recently, clinical trials are broadening eligibility to include patients with brain metastases, offering the potential for some assessment of CNS efficacy to be made. In this work we aim to review the available information on the activity of small molecule targeted drugs for advanced NSCLC with respect to CNS metastases. We analyze a framework for evaluation assessment regarding trials of systemic agents being conducted in patients with, or at risk from, CNS metastases, and provide examples of NSCLC targeted therapies evaluated in the CNS.
Insights
Central nervous system metastases are common in non-small cell lung cancer (NSCLC). This review examines targeted therapies for NSCLC brain metastases, assessing their efficacy and evaluation frameworks.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Central nervous system (CNS) metastases are a frequent complication in advanced non-small cell lung cancer (NSCLC).
- Historically, patients with brain metastases were often excluded from clinical trials, limiting efficacy data.
- Recent trial expansions now include these patients, enabling CNS efficacy assessments.
Purpose of the Study:
- To review the efficacy of small molecule targeted drugs in patients with advanced NSCLC and CNS metastases.
- To analyze evaluation frameworks for systemic agents in trials involving patients with or at risk of CNS metastases.
- To provide examples of targeted therapies for NSCLC that have been evaluated in the CNS.
Main Methods:
- Systematic literature review of clinical trials and studies.
- Analysis of trial eligibility criteria and assessment methodologies for CNS efficacy.
- Compilation and summary of data on targeted therapies evaluated in the CNS for NSCLC.
Main Results:
- Emerging data suggests activity of certain small molecule targeted drugs in NSCLC patients with CNS metastases.
- Frameworks for evaluating CNS efficacy are being developed and refined.
- Specific examples of targeted therapies demonstrating CNS activity are identified.
Conclusions:
- Small molecule targeted therapies represent a promising treatment avenue for NSCLC with CNS metastases.
- Standardized evaluation of CNS efficacy in clinical trials is crucial.
- Further research is needed to optimize treatment strategies for this patient population.
